The rapidly released PTX not only exhibits excellent inhibitory properties to GBM cells, but also sensitizes tumors to the PD-1/PD-L1 blockade by inducing ICD to facilitate ICB therapy36,37. The gene discussed is CD274; the disease is glioblastoma.